<?xml version="1.0" encoding="UTF-8"?>
<p id="Par50">In conclusion, although current NA treatment has shown clear clinical benefits, potential risks such as mitochondrial toxicity or BSC may exist, even if they do not appear to be critical. Among drugs, 2
 <sup>nd</sup> generation NA tenofovir and entecavir showed a lower impact on mitochondrial alterations compared to 1
 <sup>st</sup> generation NA combination therapy that were associated with significantly higher mitochondrial damage.
</p>
